Navigation Links
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Date:2/12/2009

NOVATO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that in the first interim efficacy analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data Monitoring Board (DMB) determined that the continuation of the trial is futile. BioMarin and partner La Jolla Pharmaceutical have decided to stop the study, unblind the data and evaluate all of the clinical results including secondary endpoints such as SLE (Systemic Lupus Erythematosus) disease activity indices and proteinuria.

"While the results of this first interim efficacy analysis are obviously disappointing, we decided to take a calculated risk on this program and with the carefully staged agreement, we have spent a total of $15 million, a relatively modest amount for a late Phase 3 asset addressing a large market opportunity," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We remain dedicated to advancing our development pipeline by making investments in future growth and continue to look for attractive late-stage in-licensing or acquisition opportunities."

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which was developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a divis
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)...  Propanc Health Group Corporation (OTCBB: PPCH) is ... development of cancer treatments for patients with pancreatic ... PRP, a patented formulation consisting of two pro-enzymes, ... the enzyme amylase designed to synergistically enhance anti-cancer ... anti-cancer agents working in combination with pro-enzymes, which ...
(Date:4/23/2015)... FRANCISCO, CA (PRWEB) April 23, 2015 ... delivery, today announced that the United States Patent and ... the Company’s NANOPOR™ technology. US Pat. ... covers Delpor’s microfabricated drug delivery device for ... Delpor’s proprietary NANOPOR™ technology for the sustained (zero-order) release ...
(Date:4/22/2015)... - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today announced that it will report ... May 7, 2015 after the close of the market. ... for 4.30 pm ET (1.30 pm PT) to discuss ... conference call will be webcast over the internet and ... media and the general public. To access the webcast ...
(Date:4/22/2015)... Steep Hill, the industry leader in ... has opened an investment round of $5 million ... common stock investment round will be offered through ... to encourage funding of small businesses by easing ... largely relied on friends and family, venture capitalists ...
Breaking Biology Technology:Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... April 10 Dedicating this year,s,Venture Forum to the ... announced a partnership in developing and producing the 2008,Life ... and,innovative seed and early-stage life sciences companies from the ... Forum will take place on,May 30, 2008, at the ...
... Medicsight PLC, a,subsidiary of MGT Capital Investments, ... in the development of Computer-Aided Detection (CAD) and ... and diagnosis of,disease, today announced that it has ... Administration ("SFDA") for its MedicRead Colon,workstation. Medicsight will ...
... -, PRINCETON, N.J., April 10, 2008 ... production,company, today announced that it has entered into ... According to the,agreement, Laureate will produce Alopexx,s mAb ... for use in clinical trials, and later,for commercial ...
Cached Biology Technology:Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 2Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 3Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation 2Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation 3Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 2Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 3
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 22, 2011) - An animal,s behavior is probably ... alike. Its behavior involves processes internal to the animalgenetics, ... and social surroundings. According to the book,s authors, "Animal ... is sparked when neurons fire in response to stimuli ...
... available in German . The ... career researchers in Germany have been chosen. The selection ... Foundation) and the German Federal Ministry of Education and ... male researchers for the Heinz Maier-Leibnitz Prize 2011. The ...
... Research Council (BBSRC) announces the signing of a Memorandum of ... and Technology (MOST) in Vietnam. This heralds the start of ... tolerance in the world,s most important staple food in the ... Funds of up to 350K are being made available by ...
Cached Biology News:New book on animal behavior provides integrated view 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 3Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 4Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 5UK-Vietnam collaboration to improve world's most important staple food 2UK-Vietnam collaboration to improve world's most important staple food 3
...
Liquid. Phycoerythrin conjugate is in PBS, pH 7.4 containing 1% BSA and 0.1% sodium azide....
... Supercoiled DNA Ladder is suitable ... 2 to 16 kb by ... bands can be visualized by ... also be detected on Southern ...
...
Biology Products: